// App-Quantinova.ai

4015 : Maintenance durvalumab after first-line platinum-based chemotherapy in advanced oesophago-gastric (OG) adenocarcinoma: Results from the PLATFORM trial.

Researchers

Presenter

  • Caroline Fong

Principal Investigators

  • Clare Peckitt

  • Elli Bourmpaki

  • Katharina von Loga

  • Ruwaida Begum

  • Michael Davidson

  • Gayathri Anandappa

  • Catherine Cafferkey

  • David J. Watkins

  • Sheela Rao

  • Tom Waddell

  • Jonathan Wadsley

  • Fareeda Coxon

  • Tom Roques

  • Carys Morgan

  • Charlotte Rees

  • Naureen Starling

  • Ian Chau

  • David Cunningham

Medical Centers

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Weston Park Hospital, Sheffield, United Kingdom

  • Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, United Kingdom

  • Paediatrics, Norfolk and Norwich University Hospitals NHS Foundation Trust,Norwich, United Kingdom

  • Velindre Cancer Centre, Cardiff, United Kingdom

  • University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Durvalumab

  • SP263

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • II

Study Id's

  • NCT02678182

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved